HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinmann, P. Articles by Lebtahi, R. Search for Related Content PubMed PubMed Citation Articles by Weinmann, P. Articles by Lebtahi, R.

¹¹¹In-Pentetreotide Scintigraphy in Patients with Langerhans' Cell Histiocytosis

Nuclear Medicine and Pneumology Departments, Avicenne Hospital, Paris; Nuclear Medicine and Pneumology Departments, Bichat Hospital, Paris; Internal Medicine Department, Pitié Hospital, Paris; and Pneumology Department, Beaujon Hospital, Paris, France

Langerhans' cell histiocytosis is a granulomatous disease that may involve multiple organs and the prognosis of which is highly variable. Because the prognosis depends particularly on the number of tissues involved, the accurate identification of the organs involved by granulomatous lesions is of critical importance. We hypothesized that ¹¹¹In-pentetreotide scintigraphy would be useful for evaluation of patients with Langerhans' cells histiocytosis. Methods: Thirteen patients (38.3 ± 10.4 y) with Langerhans' cell histiocytosis (8 patients with unifocal lung disease, 5 with multifocal disease) received intravenous ¹¹¹In-pentetreotide (111–222 MBq), and planar images were obtained at 24 h after injection. Pulmonary uptake was quantified using a lung-to-background ratio (L/B) and compared with a population of 10 normal scintigrams. For the other sites, uptake of radioactivity in disease-related areas was visually assessed. Results: Ten of 12 patients with lung involvement had increased lung uptake (L/B, 2.23 ± 0.49 versus 1.34 ± 0.07; P < 0.001). In the patients with multifocal disease, increased ¹¹¹In-pentetreotide uptake was found in disease-related areas such as the salivary glands, the skin, the soft tissues, and the bones. However, somatostatin receptor imaging was insensitive for detecting central nervous system and liver involvement and most skin lesions. Conclusion: ¹¹¹In-pentetreotide imaging may be useful in Langerhans' cell histiocytosis. Further study will indicate whether ¹¹¹In-pentetreotide is a relevant tracer in the management of histiocytosis.

Key Words: somatostatin • ¹¹¹In-pentetreotide • Langerhans' • cell histiocytosis

Received Nov. 8, 1999; revision accepted Mar. 28, 2000.

For correspondence or reprints contact: Pierre Weinmann, MD, PhD, Service de Médecine Nucléaire, Hôpital Avicenne, 125 Rue de Stalingrad, Bobigny Cedex, 93009 France.

This article has been cited by other articles:

				R. Lebtahi, S. Moreau, S. Marchand-Adam, M.-P. Debray, M. Brauner, P. Soler, J. Marchal, O. Raguin, A. Gruaz-Guyon, J.-C. Reubi, et al. Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis J. Nucl. Med., August 1, 2006; 47(8): 1281 - 1287. [Abstract] [Full Text] [PDF]

				A. Tazi Adult pulmonary Langerhans' cell histiocytosis. Eur. Respir. J., June 1, 2006; 27(6): 1272 - 1285. [Abstract] [Full Text] [PDF]

				F. Darvishian, S. Hirawat, S. Teichberg, D. Wolk, S. L. Allen, and S. I. Hajdu Langerhans' Cell Histiocytosis in the Parotid Gland Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 201 - 206. [Abstract] [Full Text] [PDF]